Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse-Reference-Cited by-同舟云学术

Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse

Published:2023-04-25 Issue:8 Volume:58 Page:849-854
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Kent Andrew,Schwartz Marc,McMahon Christine,Amaya Maria,Smith Clayton A.,Tobin Jennifer,Marciano Kelsey,Rezac Rebecca,Bosma Grace,Pollyea Daniel A.,Gutman Jonathan A.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01987-5.pdf

Reference42 articles.

1. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v158–161. https://doi.org/10.1093/annonc/mdq179.

2. Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol. 2012. https://doi.org/10.1097/CCO.0b013e32834f5c41.

3. van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010;16:S138–145. https://doi.org/10.1016/j.bbmt.2009.10.023.

4. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21:454–9. https://doi.org/10.1016/j.bbmt.2014.11.007.

5. Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26:6475–82. https://doi.org/10.1158/1078-0432.CCR-20-3134.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC);Bulletin du Cancer;2024-09

2. Precision medicine in AML: overcoming resistance;International Journal of Hematology;2024-08-01

3. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients;British Journal of Haematology;2024-07-31

4. Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?;Leukemia & Lymphoma;2024-07-23

5. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?;Expert Review of Hematology;2024-07-21